Response to "Hepatitis C Virus, Sickle Cell Disease Treatment Options" - A February Letter to the Editor [2]

Journal of the National Medical Association

Volumn 96, Issue 3, 2004, Pages 383-

  Smoot, Duane T ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; INTERFERON; IRON CHELATE; RIBAVIRIN;

CHRONIC LIVER DISEASE; HEMOLYSIS; HEPATITIS C VIRUS; HUMAN; IRON CHELATION; IRON OVERLOAD; LETTER; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; PATIENT REFERRAL; PHLEBOTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TREATMENT CONTRAINDICATION; TREATMENT PLANNING;

ANEMIA, SICKLE CELL; ANTIVIRAL AGENTS; COMORBIDITY; HEPATITIS C; HUMANS; INTERFERONS; IRON CHELATING AGENTS; RIBAVIRIN;

EID: 1442355838     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Hepatitis C Infection in Sickle Cell Disease: Review of the Literature. Hassan M, Hasan S, Castro O, et al. J Natl Med Assoc. 95;9:864-874.
2. Swaim MW, Agarwak S, Rosse W. Successful treatment of hepatitis C in sickle cell disease (correspondence). Ann Intern Med. 2000;133:750-751.